2024 DxPx U.S. Startups
EXHIBITING IN STARTUP CITY:
Ad Astra Diagnostics
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/aad.png)
Ad Astra Diagnostics, Inc. (AAD) is developing the fastest need-to-result complete blood count in a rugged, easy-to-use, patient-side system designed to go anywhere. AAD’s QScoutTM RLD is the only FDA cleared test to quantitate at point of care immature granulocytes, a sepsis marker. AAD develops rapid diagnostic and data systems that enable fast point of care health decisions to support its vision of making diagnostics more accessible.
For more information, visit: https://www.adastradx.com/
Allergios
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/allergios1.png)
Allergios is an innovative startup specializing in advanced allergy diagnostics. The company operates in the healthcare sector, focusing on providing precise and direct allergy diagnosis through cutting-edge technology.
For more information, visit: https://allergios.health/
BacterOMIC
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/bacteromic.png)
BACTEROMIC develops the most informative Antibiotic Susceptibility Testing system designed to assess antimicrobial resistance against even all clinically-relevant antibiotics in a single test. The highly versatile system is set to provide the most precise information about the optimal treatment and MIC level with an ultimate goal of results under 6-8h. Currently, BACTEROMIC has a first UNI25 Panel certified in the EU and develops new product - Positive Blood Culture Panel addressing bloodstream infections.
For more information, visit: https://bacteromic.com/
DoMore Diagnostics
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/domore.png)
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
For more information, visit: https://www.domorediagnostics.com/
Enzyre
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/Enzyre.png)
Enzyre was founded with the mission to develop innovative diagnostic solutions to enable personalized medicine. The company holds the vision to create a point of care (POC) diagnostic platform that will measure a multitude of enzymatic reactions based on chemiluminescence.
For more information, visit: https://enzyre.com/
expressTEC
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/expresstech1.png)
expressTec is a female-founded biotech startup dedicated to advancing personalized cancer therapy. Our mission is to enable and accelerate the accurate matching of targeted therapies to patients. Through our innovative RNA-based approaches, we aim to revolutionize clinical testing, optimize treatment outcomes, reduce side effects, and enhance the quality of life for cancer patients.
For more information, visit: https://expresstec.pt/
FluidAI Medical
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/fluidai.png)
FluidAI Medical focuses on data-driven patient recovery following surgery. FluidAI's groundbreaking Stream Platform leverages AI to predict surgical outcomes and postoperative complications after general and gastrointestinal surgeries. The Stream Platform includes the Stream app, which utilizes AI to generate a predictive risk score using data from the patient's health record, and FluidAI's proprietary data source, Origin, which continuously and non-invasively analyzes postoperative wound drainage to prompt surgeons of potential complications as they develop
For more information, visit: https://fluidai.md/
Genomtec SA
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/genomtec.jpg)
Genomtec is an innovative technology company developing a unique mobile point of care genetic testing platform for the clinical diagnostics market. The company has platform technology that can enable Point of Care Infectious Diseases diagnostics and companion diagnostics for Oncology. Its microfluidic lab-on-chip platform uses a patented non-contact heating and detection system and a proprietary LAMP based isothermal amplification methods. The company's first asset is a multiplexed molecular diagnostics assay that can rapidly identify Influenza A/B, RSV A/B, SARS-CoV-2 and M.pneumoniae pathogens. Genomtec is currently working on EGFR markers in non-small cell Lung Cancer. The company is looking for strategic partnership opportunities for CDx menu development, M&A, and OEM licensing.
For more information, visit: www.genomtec.com
LoBio
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/lobio.png)
LoBio is reimagining the future of blood testing with a patented blood/plasma separation technology that replaces the centrifuge. Its product, the P1™, allows anyone to collect high-quality plasma from the comfort of their home within minutes. LoBio is financially backed by industry and operating experts who are graduates of several prestigious accelerator programs including Techstars Healthcare ’24 and Creative Destruction Lab ’24.
For more information, visit: https://www.lobiosci.com/
NADMED
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/nadmed.jpg)
NADMED is a developer of NAD measuring technology designed for extracting and measuring nicotinamide adenine dinucleotides and glutathiones. The company’s technology is based on the novel nondestructive extraction of metabolites and colourimetric quantification and has been used to study research samples of cells, liver, brain, muscle, and blood of human or animal origin.
For more information, visit: www.nadmed.com
NeoPredix
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/neopredix.png)
NeoPredix creates intelligent digital health solutions that facilitate decision making in clinical practice. Our goal is to improve the lives of children and their families, avoid unnecessary hospital stays, and reduce health care costs.
For more information, visit: https://neopredix.com/us/
Pamgene
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/pamgene.jpg)
PamGene is a Dutch biotech company that supports scientists and companies in finding biomarker solutions using an innovative, multiplex kinome profiling technology. PamGene has recently registered two CE-IVD blood tests to help physicians improving the outcome of cancer patients treated with immune checkpoint blockers. Through the support of oncologists and their patients the IOpener® blood test can now be successfully initiated in the diagnostic market for melanoma and lung cancer.
For more information, visit: https://pamgene.com/
Pangea Laboratory
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/pangea.jpg)
Pangea Laboratory is a Southern Californian-based CAP-accredited and CLIA-certified facility, focusing on urinary epigenetic oncology diagnostics, with bench-strength in Next Generation Sequencing for research and industrial applications.
For more information, visit: https://pangealab.com/
Prolight Diagnostics
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/prolight.gif)
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Prolight wants to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Its launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
For more information, visit: https://prolightdx.com/en/
Sciomics GmbH
![](https://events.jspargo.com/ADLM24//custom/images/dxpx/sciomics.png)
Sciomics offers robust immune-based proteomics for biomarker development. Explore its CRO services or partner with the company to advance AKI diagnostics to the market.
For more information, visit: https://www.sciomics.de/